Filing Flows › CytomX Therapeutics (CTMX) › Q3 2025
CytomX Therapeutics (CTMX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
CytomX Therapeutics (CTMX) reported revenue of $6.0M for the third quarter 2025 (Q3 2025), -82% from a year earlier and -68% from the quarter before. Operating margin was -264.4%, net loss $14.2M (238.6% of revenue).
CytomX Therapeutics, Q3 2025: revenue $6.0M (-82% year over year), operating margin -264.4%, net loss $14.2M, operating cash flow −$15.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.0M | -68% | -82% |
| Operating profit | −$15.8M | — | — |
| Net earnings | −$14.2M | — | — |
| Operating cash flow | −$15.5M | — | — |
What changed
Revenue was $6.0M in Q3 2025, down 82% year over year and down 68% from the previous quarter.
Operating costs exceeded revenue by $15.8M, an operating margin of -264.4%. Total costs fell 26% while revenue fell 82%. The quarter ended with a net loss of $14.2M, wider than the previous quarter's $154K loss.
Operating cash flow was −$15.5M. Non-cash charges added back $1.4M of share-based compensation. Working capital and other items used $2.7M. Capital expenditures of −$127K exceeded it, leaving free cash flow of −$15.4M.
Questions
What was CytomX Therapeutics' revenue in the third quarter 2025?
CytomX Therapeutics (CTMX) reported revenue of $6.0M for the third quarter 2025 (Q3 2025), -82% from a year earlier and -68% from the quarter before.
Was CytomX Therapeutics profitable in the third quarter 2025?
Operating loss was $15.8M (-264.4% of revenue) and net loss $14.2M.